NCT03870503View on ClinicalTrials.gov

Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage

NACompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

August 1, 2021

Conditions

Postpartum Hemorrhage

Interventions

DRUG

oxytocin

The patient will be received oxytocin 20 IU by intravenous infusion

DRUG

oxytocin plus misoprostol

The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol

DRUG

Carbetocin

The patient received Carbetocin 100 mic gm

Trial Locations (1)

81528

Aswan University Hospital, Aswān

All Listed Sponsors

lead

Aswan University Hospital

OTHER

NCT03870503 - Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage | Biotech Hunter | Biotech Hunter